BD Launches Enhanced Intraosseous System, Enabling Vascular Access in Seconds for Critical Care Situations
BD (NYSE: BDX) has launched the new BD® Intraosseous Vascular Access System, designed for rapid delivery of fluids or medication in emergency situations where IV access is challenging. The system features unique advantages including placement capability after extension set attachment and integrated passive needle tip safety. The device offers five needle length options and includes a rechargeable battery that lasts up to 12 times longer than competitors'. Clinical studies show trained users achieve a 93-97% success rate in IO placement, with less than 1% chance of serious complications. The system is now available in the U.S. market.
BD (NYSE: BDX) ha lanciato il nuovo Sistema di Accesso Vascolare Intraosseo BD®, progettato per la rapida somministrazione di liquidi o farmaci in situazioni di emergenza in cui l'accesso IV è difficile. Il sistema presenta vantaggi unici, tra cui la possibilità di posizionamento dopo l'attacco del set di estensione e la sicurezza integrata della punta dell'ago passiva. Il dispositivo offre cinque opzioni di lunghezza dell'ago e include una batteria ricaricabile che dura fino a 12 volte più a lungo rispetto ai competitor. Studi clinici dimostrano che gli utenti formati raggiungono un tasso di successo del 93-97% nel posizionamento IO, con meno dell'1% di probabilità di complicazioni gravi. Il sistema è ora disponibile nel mercato statunitense.
BD (NYSE: BDX) ha lanzado el nuevo Sistema de Acceso Vascular Intraóseo BD®, diseñado para la rápida administración de fluidos o medicamentos en situaciones de emergencia donde el acceso IV es complicado. El sistema cuenta con ventajas únicas, incluida la capacidad de colocación después de la conexión del set de extensión y la seguridad integrada de la punta de la aguja pasiva. El dispositivo ofrece cinco opciones de longitud de aguja e incluye una batería recargable que dura hasta 12 veces más que la de la competencia. Los estudios clínicos muestran que los usuarios capacitados alcanzan una tasa de éxito del 93-97% en la colocación IO, con menos del 1% de posibilidades de complicaciones graves. El sistema ya está disponible en el mercado estadounidense.
BD (NYSE: BDX)는 IV 접근이 어려운 응급 상황에서 액체나 약물을 신속하게 전달하기 위해 설계된 BD® 골수혈관 접근 시스템을 출시했습니다. 이 시스템은 연장 세트 연결 후 배치 가능성 및 통합 패시브 바늘 팁 안전성을 포함한 독특한 장점을 제공합니다. 장치는 다섯 가지 바늘 길이 옵션을 제공하며, 경쟁업체보다 최대 12배 더 긴 배터리 수명을 가진 재충전 가능한 배터리를 포함합니다. 임상 연구 결과에 따르면 훈련된 사용자들은 IO 배치에서 93-97%의 성공률을 달성하며, 심각한 합병증의 가능성은 1% 미만입니다. 이 시스템은 현재 미국 시장에서 이용 가능합니다.
BD (NYSE: BDX) a lancé le nouveau Système d'Accès Vasculaire Intraosseux BD®, conçu pour la délivrance rapide de fluides ou de médicaments dans des situations d'urgence où l'accès IV est difficile. Le système présente des avantages uniques, notamment la possibilité de placement après la connexion de l'ensemble d'extension et la sécurité intégrée de la pointe d’aiguille passive. L'appareil propose Cinq options de longueur d’aiguille et comprend une batterie rechargeable d'une autonomie allant jusqu'à 12 fois plus longue que celle des concurrents. Des études cliniques montrent que les utilisateurs formés atteignent un taux de réussite de 93-97% dans le placement IO, avec moins de 1% de risque de complications graves. Le système est désormais disponible sur le marché américain.
BD (NYSE: BDX) hat das neue BD® Intraossäres Gefäßzugangssystem auf den Markt gebracht, das für die schnelle Verabreichung von Flüssigkeiten oder Medikamenten in Notfallsituationen konzipiert wurde, in denen der IV-Zugang schwierig ist. Das System bietet einzigartige Vorteile, darunter die Platzierungsmöglichkeit nach der Anbringung des Verlängerungssets und die integrierte Sicherheit der passiven Nadelspitze. Das Gerät bietet fünf Nadel-Längenoptionen und enthält einen wiederaufladbaren Akku, der bis zu 12 Mal länger hält als die Konkurrenz. Klinische Studien zeigen, dass ausgebildete Benutzer eine Erfolgsquote von 93-97% bei der IO-Platzierung erreichen, mit weniger als 1% Wahrscheinlichkeit für schwerwiegende Komplikationen. Das System ist jetzt auf dem US-Markt erhältlich.
- Only IO device allowing placement after extension set attachment
- Rechargeable battery lasting 12x longer than competitors
- 93-97% placement success rate in clinical studies
- Less than 1% chance of serious complications
- Twice as likely to be successfully placed compared to IV or central venous catheter in critical situations
- None.
Insights
The enhanced BD Intraosseous System represents a significant advancement in emergency medical technology. The system's innovative features - including the unique ability to place after extension set attachment and integrated passive needle safety - address critical clinical needs and differentiate it from competitors. The rechargeable battery feature offering 12x longer life demonstrates strong operational efficiency.
The market opportunity is substantial, considering emergency departments, ambulatory services and military medical units. With a
This product launch strengthens BD's position in the emergency medical devices sector. The timing is strategic as healthcare facilities focus on improving emergency response capabilities and reducing medical errors. The system's comprehensive features address key market demands: safety, reliability and efficiency.
The reusable design with rechargeable battery offers significant cost advantages for healthcare providers compared to single-use alternatives. Given BD's extensive distribution network and strong brand presence in medical devices, this product should see rapid market adoption. While specific revenue projections aren't provided, the product's competitive advantages and large addressable market in emergency care suggest positive impact on BD's medical solutions segment growth.
The BD® IO System can quickly provide access to the circulatory system for adult and pediatric patients and is built for rapid intervention in varied emergent care environments. The BD® IO System is the only IO device on the market that can be placed after the extension set is attached and the only with integrated passive needle tip safety, designed to protect care providers and patients against needlestick injuries. Clinicians can stabilize the device on the contours of any surrounding anatomy and select from five needle lengths to accommodate a broad range of patients. Unlike other devices on the market, the powered driver features a rechargeable battery, which extends the life of the drill up to 12 times when compared to non-rechargeable competitive drills. Its unique multi-light battery indicator provides an instant indication of battery status so clinicians can be confident the drill is powered for the procedure.
"In emergency situations, mistakes and delays can have devastating consequences," said Eric Borin, worldwide president of Medication Delivery Solutions at BD. "This important innovation represents a significant advancement in rapid vascular access and builds on our ongoing commitment to support medical teams in delivering the highest-quality access and improving patient outcomes during lifesaving emergency health situations."
IO access provides a non-collapsible, stable space for the safe administration of any medication or fluids that can also be administered through an IV1,2. IO placement is regarded to be a relatively safe procedure, with a less than one percent chance of serious complications3,4. In critical situations, such as patients with low or no palpable blood pressure, the placement of an IO was twice as likely to be successfully placed compared to placement of a peripheral IV or central venous catheter5. Studies show that trained inserters achieve a 93–97 percent IO placement success rate4.
BD® IO System is now commercially available to customers in the
About BD
BD is one of the largest global medical technology companies in the world and is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. The company supports the heroes on the frontlines of health care by developing innovative technology, services and solutions that help advance both clinical therapy for patients and clinical process for health care providers. BD and its more than 70,000 employees have a passion and commitment to help enhance the safety and efficiency of clinicians' care delivery process, enable laboratory scientists to accurately detect disease and advance researchers' capabilities to develop the next generation of diagnostics and therapeutics. BD has a presence in virtually every country and partners with organizations around the world to address some of the most challenging global health issues. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase efficiencies, improve safety and expand access to health care. For more information on BD, please visit bd.com or connect with us on LinkedIn at www.linkedin.com/company/bd1/, X (formerly Twitter) @BDandCo or Instagram @becton_dickinson.
Contacts:
Media: Investors:
Troy Kirkpatrick Adam Reiffe
VP, Public Relations Sr. Director, Investor Relations
858.617.2361 201.847.6927
troy.kirkpatrick@bd.com adam.reiffe@bd.com
1 Phillips L, Brown L, Campbell T, Miller J, Proehl J, Youngberg B. Recommendations for the Use of Intraosseous Vascular Access for Emergent and Nonemergent Situations in Various Healthcare Settings: A Consensus Paper. Journal of Emergency Nursing. 2010;36(6):551-556. doi:https://doi.org/10.1016/j.jen.2010.09.001
2 BD Intraosseous Vascular Access System market research.
3 Bs J, Thompson J. Intraosseous Device Insertion for Adults and Pediatrics. Accessed November 22, 2023. https://cdn.ymaws.com/www.avainfo.org/resource/resmgr/files/position_statements/ava_position_paper_-_intraos.pdf
4 UpToDate. www.uptodate.com. https://www.uptodate.com/contents/intraosseous-infusion
5 Chreiman KM, Dumas RP, Seamon MJ, et al. The intraosseous have it. Journal of Trauma and Acute Care Surgery. 2018;84(4):558-563. doi:https://doi.org/10.1097/ta.0000000000001795
View original content to download multimedia:https://www.prnewswire.com/news-releases/bd-launches-enhanced-intraosseous-system-enabling-vascular-access-in-seconds-for-critical-care-situations-302290569.html
SOURCE BD (Becton, Dickinson and Company)
FAQ
What are the key features of BD's new Intraosseous Vascular Access System (BDX)?
What is the success rate of BD's Intraosseous System (BDX)?
When did BD (BDX) launch its new Intraosseous Vascular Access System?
Is BD's Intraosseous System (BDX) available in the United States?
